

DAFTAR PUSTAKA

- Ait-Daoud, N., Hamby, A.S., Sharma, S., dan Blevins, D., 2018. A Review of Alprazolam Use, Misuse, and Withdrawal. *Journal of Addiction Medicine*, **12**: 4–10.
- American Addiction Centers, 2020. 'Treating Addiction with Anxiety Disorders', *American Addiction Centers*. URL: <https://americanaddictioncenters.org/anxiety-and-addiction> (diakses tanggal 24/4/2020).
- American Psychiatric Association (Editor), 2013. Anxiety Disorder, dalam: *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. American Psychiatric Association, Washington, D.C, hal. 227–272.
- Amirullah, A., 2019. 'Pengaruh Penggunaan Alprazolam On-Label dan Off-Label Terhadap Outcome Klinik', *Tesis, M.Sc.*, Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta.
- Arulsamy, A. dan Shaikh, M., 2016. The Impact of Epilepsy on the Manifestation of Anxiety Disorder. *International Journal of Nutrition, Pharmacology, Neurological Diseases*, **6**: 3–11.
- Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A.A., dkk., 2009. Benzodiazepine Dependence: Focus on Withdrawal Syndrome. *Annales Pharmaceutiques Françaises*, **67**: 408–413.
- Bandelow, B., 2006. Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach. *CNS Spectrums*, **11**: 21–28.
- Bandelow, B., Michaelis, S., dan Wedekind, D., 2017. Treatment of Anxiety Disorders. *Dialogues in Clinical Neuroscience*, **19**: 15.
- Batelaan, N.M., Bosman, R.C., Muntingh, A., Scholten, W.D., dan Huijbregts, K.M., 2017. Risk of Relapse After Antidepressant Discontinuation in Anxiety Disorders, Obsessive-Compulsive Disorder, and Post-Traumatic Stress Disorder: Systematic Review and Meta-Analysis of Relapse Prevention Trials. *British Medical Journal*, **358**: 12.

- Batelaan, N.M., de Graaf, R., Penninx, B.W.J.H., van Balkom, A.J.L.M., Vollebergh, W.A.M., dan Beekman, A.T.F., 2009. The 2-Year Prognosis of Panic Episodes in The General Population. *Psychological Medicine*, **40**: 147–157.
- Birkett, M.A. dan Day, S.J., 1994. Internal Pilot Studies for Estimating Sample Size. *Statistics in Medicine*, **13**: 2455–2463.
- Bonn-Miller, M.O. dan Moos, R.H., 2009. Marijuana Discontinuation, Anxiety Symptoms, and Relapse to Marijuana. *Addictive Behaviors*, **34**: 782–785.
- Brady, K.T., Haynes, L.F., Hartwell, K.J., dan Killeen, T.K., 2013. Substance Use Disorders and Anxiety: A Treatment Challenge for Social Workers. *Social Work in Public Health*, **28**: 407–423.
- Bruce, S.E., Yonkers, K.A., dan Otto, M.W., 2005. Influence of Psychiatric Comorbidity on Recovery and Recurrence in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder: A 12-Year Prospective Study. *Am J Psychiatry*, **162**: 1179–1187.
- Brunette, M.F., Noordsy, D.L., Xie, H., dan Drake, R.E., 2003. Benzodiazepine Use and Abuse Among Patients With Severe Mental Illness and Co-occurring Substance Use Disorders. *Psychiatric Services*, **54**: 1395–1401.
- Burns, L., Teesson, M., dan O'Neill, K., 2005. The Impact of Comorbid Anxiety and Depression on Alcohol Treatment Outcomes. *Society for the Study of Addiction*, **100**: 787–796.
- Campbell, A., Bailey, S.R., Hoffman, K.A., Ponce-Terashima, J., Fankhauser, K., Marino, M., dkk., 2020. Associations between Psychiatric Disorders and Cannabis-Related Disorders Documented in Electronic Health Records. *Journal of Psychoactive Drugs*, **52**: 228–236.
- Center for Behavioral Health Statistics and Quality, 2016. '2015 National Survey on Drug Use and Health: Detailed Tables', . Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, Maryland.
- Chowdhury, Z.S., Morshed, M.M., Shahriar, M., Bhuiyan, M.A., Islam, S.Mohd.A., dan Bin Sayeed, M.S., 2016. The Effect of Chronic Alprazolam

Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers. *Behavioural Neurology*, **2016**: 1–9.

Ciraulo, D.A., Barnhill, J.G., Ciraulo, A.M., Sarid-Segal, O., Knapp, C., Greenblatt, D.J., dkk., 1997. Alterations in Pharmacodynamics of Anxiolytics in Abstinent Alcoholic Men: Subjective Responses, Abuse Liability, and Electroencephalographic Effects of Alprazolam, Diazepam, and Buspirone. *The Journal of Clinical Pharmacology*, **37**: 64–73.

Cloos, J.-M. dan Ferreira, V., 2009. Current Use of Benzodiazepines in Anxiety Disorders. *Current Opinion in Psychiatry*, **22**: 90–95.

Conn, D.K., Hogan, D.B., Amdam, L., Cassidy, K.-L., Cordell, P., Frank, C., dkk., 2019. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. *Canadian Geriatrics Journal*, **23**: 116–122.

Dahlan, M.S., 2010. *Besar Sampel Dan Cara Pengambilan Sampel*, Seri 2. ed. Salemba Medika, Jakarta.

Deacon, B.J. dan Abramowitz, J.S., 2005. Patients' Perceptions of Pharmacological and Cognitive-Behavioral Treatments for Anxiety Disorders. *Behavior Therapy*, **36**: 139–145.

Denys, D. dan de Geus, F., 2005. Predictors of Pharmacotherapy Response in Anxiety Disorders. *Current Psychiatry Reports*, **7**: 252–257.

Depping, A.M., Komossa, K., Kissling, W., dan Leucht, S., 2010. Second-Generation Antipsychotics for Anxiety Disorders. *Cochrane Database of Systematic Reviews*, .

Driessen, M., 2001. The Course of Anxiety, Depression and Drinking Behaviours After Completed Detoxification in Alcoholics With and Without Comorbid Anxiety and Depressive Disorders. *Alcohol and Alcoholism*, **36**: 249–255.

Fujii, K., Uchida, H., Suzuki, T., dan Mimura, M., 2015. Dependence on Benzodiazepines in Patients with Panic Disorder: A Cross-Sectional Study. *Psychiatry and Clinical Neurosciences*, **69**: 93–99.

Ginsburg, G.S., Kendall, P.C., Sakolsky, D., Compton, S.N., Piacentini, J., Albano, A.M., dkk., 2011. Remission After Acute Treatment in Children and

Adolescents with Anxiety Disorders: Findings from the CAMS. *Journal of Consulting and Clinical Psychology*, **79**: 806–813.

Gomez, A.F., Barthel, A.L., dan Hofmann, S.G., 2018. Comparing the Efficacy of Benzodiazepines and Serotonergic Anti-Depressants for Adults with Generalized Anxiety Disorder: a Meta-Analytic Review. *Expert Opinion on Pharmacotherapy*, **19**: 883–894.

Goodwin, R.D. dan Stein, D.J., 2013. Anxiety Disorders and Drug Dependence: Evidence on Sequence and Specificity Among Adults. *Psychiatry and Clinical Neurosciences*, **67**: 167–173.

Grinchii, D. dan Dremencov, E., 2020. Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. *International Journal of Molecular Sciences*, **21**: 1–15.

Gupta, S. dan Kulhara, P., 2007. Cellular and Molecular Mechanisms of Drug Dependence: An Overview and Update. *Indian Journal of Psychiatry*, **49**: 85–90.

Guthrie, S.K. dan Bostwick, J.R., 2013. Anxiety Disorder, dalam: Koda-Kimble, M.A. dan Alldredge, B.K. (Editor), *Applied Therapeutics: The Clinical Use of Drugs*. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.

Hershenberg, R., Gros, D.F., dan Brawman-Mintzer, O., 2014. Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder. *CNS Drugs*, **28**: 519–533.

Iii, C.E.G., Kaye, A.M., dan Kaye, A.D., 2013. Benzodiazepine Pharmacology and Central Nervous System–Mediated Effects **13**: 10.

Ikawati, Z. dan Anurogo, D., 2018. *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat*. Bursa Ilmu, Yogyakarta.

In, J., 2017. Introduction of a Pilot Study. *Korean Journal of Anesthesiology*, **70**: 601.

Jessell, L., Stanhope, V., Manuel, J.I., dan Mateu-Gelabert, P., 2020. Factors Associated with Benzodiazepine Prescribing in Community Mental Health Settings. *Journal of Substance Abuse Treatment*, **109**: 56–60.

- Jung, M.E., Metzger, D.B., dan Hall, J., 2020. The Long-Term but Not Short-Term Use of Benzodiazepine Impairs Motoric Function and Upregulates Amyloid β in Part Through the Suppression of Translocator Protein. *Pharmacology Biochemistry and Behavior*, **191**: 172873.
- Kader Maideen, S.F., Mohd Sidik, S., Rampal, L., dan Mukhtar, F., 2015. Prevalence, Associated Factors and Predictors of Anxiety: a Community Survey in Selangor, Malaysia. *BMC Psychiatry*, **15**: 262.
- Kaplan, E.M. dan DuPont, R.L., 2005. Benzodiazepines and Anxiety Disorders: a Review for the Practicing Physician. *Current Medical Research and Opinion*, **21**: 941–950.
- Kariuki-Nyuthe, C. dan Stein, D.J., 2015. Anxiety and Related Disorders and Physical Illness. *Key Issues in Mental Health*, **179**: 81–87.
- Kasper, S., Herman, B., Nivoli, G., Ameringen, M.V., Petralia, A., Mandel, F.S., dkk., 2009. Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial: *International Clinical Psychopharmacology*, **24**: 87–96.
- Katzman, M.A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., dkk., 2014. Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders. *BMC Psychiatry*, **14**: S1.
- Kedzior, K.K. dan Laeber, L.T., 2014. A Positive Association Between Anxiety Disorders and Cannabis Use or Cannabis Use Disorders in the General Population- a Meta-Analysis of 31 Studies. *BMC Psychiatry*, **14**: 22.
- Kehoe, W.A., 2017. Generalized Anxiety Disorder. *ACSAP*, 7–27.
- Keks, N., 2016. Switching and Stopping Antidepressants. *Australian Prescriber*, **39**: 76–83.
- Kelly, K.M. dan Mezuk, B., 2017. Predictors of Remission From Generalized Anxiety Disorder and Major Depressive Disorder. *Journal of Affective Disorders*, **208**: 467–474.

Kemenkes RI, 2018. *Riset Kesehatan Dasar 2018*. Kementerian Kesehatan RI, Jakarta.

Klein, E., Colin, V., Stolk, J., dan Lenox, R.H., 1995. Alprazolam Withdrawal in Patients With Panic Disorder and Generalized Anxiety Disorder: Vulnerability and Effect of Carbamazepine. *Am J Psychiatry*, **151**: 1760–1766.

Lader, M., 2012. Benzodiazepine Harm: How Can it be Reduced? *British Journal of Clinical Pharmacology*, **77**: 295–301.

Lemeshow, S., Hosmer Jr., D.W., Klar, J., dan Lwanga, S.K. (Editor), 1990. *Adequacy of Sample Size in Health Studies*. World Health Organization by John Wiley & Sons, West Sussex, England.

Locke, A.B., 2015. Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults. *American Academy of Family Physician*, **91**: 617–624.

Maier, W., Buller, R., Philipp, M., dan Heuser, I., 1988. The Hamilton Anxiety Scale: Reliability, Validity and Sensitivity to Change in Anxiety and Depressive Disorders. *Journal of Affective Disorders*, **14**: 61–68.

Mak, A.D.P., Wu, J.C.Y., Chan, Y., Chan, F.K.L., Sung, J.J.Y., dan Lee, S., 2012. Dyspepsia is Strongly Associated with Major Depression and Generalised Anxiety Disorder - a community study. *Alimentary Pharmacology & Therapeutics*, **36**: 800–810.

McHugh, R.K., 2015. Treatment of Co-occurring Anxiety Disorders and Substance Use Disorders: *Harvard Review of Psychiatry*, **23**: 99–111.

McRae, A.L., Sonne, S.C., Brady, K.T., Durkalski, V., dan Palesch, Y., 2004. A Randomized, Placebo- controlled trial of Buspirone for the Treatment of Anxiety in Opioid-dependent Individuals. *American Journal on Addictions*, **13**: 53–63.

Melton, S.T. dan Kikwood, C.K., 2017. Anxiety Disorders : Generalized Anxiety, Panic, ad Social Anxiety Disorder, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M. (Editor),

Pharmacotherapy A Pathophysiologic Approach. Mc Graw Hill, New York, hal. 3067–3116.

Miller, S.C., Fiellin, D.A., Rosenthal, R.N., Saitz, R., dan American Society of Addiction Medicine (Editor), 2019. *The ASAM Principles of Addiction Medicine*, Sixth edition. ed. Wolters Kluwer, Philadelphia.

Mills, P.S., 2011. 'ASAM's State of the Art Course Sets New Records', . *American Society of Addiction Medicine*, 23.

Mueller, T.I., Pagano, M.E., Rodriguez, B.F., Bruce, S.E., Stout, R.L., dan Keller, M.B., 2005. Long-Term Use of Benzodiazepines in Participants with Comorbid Anxiety and Alcohol Use Disorders: *Alcoholism: Clinical & Experimental Research*, 29: 1411–1418.

Mula, M., Pini, S., dan Cassano, G.B., 2007. The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence. *Journal of Clinical Psychopharmacology*, 27: 263–272.

National Institute for Health and Clinical Excellence, 2004. 'Interventions for Generalised Anxiety Disorder', *Clinical Guidelines for the Management of Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care [Internet]*. URL: <https://www.ncbi.nlm.nih.gov/books/NBK45827/> (diakses tanggal 31/3/2020).

National Institute for Health and Clinical Excellence, 2011. 'Generalised Anxiety Disorder and Panic Disorder in Adults: Management', *NICE*. URL: <https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance> (diakses tanggal 1/5/2020).

O'Brien, P.L., Karnell, L.H., Gokhale, M., Kenneth Pack, B.S., Campopiano, M., dan Zur, J., 2017. Prescribing of Benzodiazepines and Opioids to Individuals with Substance Use Disorders. *Drug and Alcohol Dependence*, 178: 223–230.

Offidani, E., Guidi, J., Tomba, E., dan Fava, G.A., 2013. Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis. *Psychotherapy and Psychosomatics*, 82: 355–362.

Ogbonna, C.C.I., Jose, K.P.S., dan Jose, S., 2017. Tapering Patients Off of Benzodiazepines. *American Academy Family Physician*, **96**: 3.

Pollack, M.H., Simon, N.M., Worthington, J.J., Doyle, A.L., Peters, P., Toshkov, F., dkk., 2003. Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder. *Journal of Psychopharmacology*, **17**: 276–282.

Posternak, M.A. dan Mueller, T.I., 2001. Assessing the Risks and Benefits of Benzodiazepines for Anxiety Disorders in Patients with a History of Substance Abuse or Dependence. *American Journal on Addictions*, **10**: 48–68.

Preston, C.L., 2015. *Stockley's Drug Interactions 2015*. Pharmaceutical Press, London.

Raj, K.S., Williams, N., dan DeBattista, C., 2019. Psychiatric Disorders, dalam: Papadakis, M.A. dan McPhee, S.J. (Editor), *Current Medical Diagnosis & Treatment 2019*. McGraw-Hill Education, New York, hal. 1063–1118.

Ramsawh, H.J., Weisberg, R.B., Dyck, I., Stout, R., dan Keller, M.B., 2011. Age of Onset, Clinical Characteristics, and 15-year Course of Anxiety Disorders in a Prospective, Longitudinal, Observational Study. *Journal of Affective Disorders*, **132**: 260–264.

Reissig, C.J., Harrison, J.A., Carter, L.P., dan Griffiths, R.R., 2015. Inhaled vs Oral Alprazolam: Subjective, Behavioral and Cognitive Effects, and Modestly Increased Abuse Potential. *Psychopharmacology*, **232**: 871–883.

Republik Indonesia, 2009. *Undang-Undang Republik Indonesia Nomor 35 tahun 2009 tentang Narkotika*. Lembaran Negara Republik Indonesia Tahun 2009 Nomor 143, Jakarta.

Rickels, K., Shiovit, T.M., Ramey, T.S., Weaver, J.J., Knapp, L.E., dan Miceli, J.J., 2012. Adjunctive Therapy with Pregabalin in Generalized Anxiety Disorder Patients with Partial Response to SSRI or SNRI Treatment. *International Clinical Psychopharmacology*, **27**: 142–150.

Rodriguez, B.F., Weisberg, R.B., Pagano, M.E., Bruce, S.E., Spencer, M.A., Culpepper, L., dkk., 2006. Characteristics and Predictors of Full and Partial

Recovery From Generalized Anxiety Disorder in Primary Care Patients. *The Journal of Nervous and Mental Disease*, **194**: 91–97.

Sadock, B.J., Sadock, V.A., dan Ruiz, P., 2015. Anxiety Disorder, dalam: *Kaplan & Sadock's Synopsis Of Psychiatry: Behavioral Sciences/Clinical Psychiatry*. Wolters Kluwer, hal. 832–904.

SAMHSA, 2014. 'Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings', . Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, Maryland.

Shinfuku, M., Kishimoto, T., Uchida, H., Suzuki, T., Mimura, M., dan Kikuchi, T., 2019. Effectiveness and Safety of Long-term Benzodiazepine Use in Anxiety Disorders: a Systematic Review and Meta-analysis. *International Clinical Psychopharmacology*, **34**: 211–221.

Simpson, H.B., Liebowitz, M.R., Foa, E.B., Kozak, M.J., Schmidt, A.B., Rowan, V., dkk., 2004. Post-Treatment Effects of Exposure Therapy and Clomipramine in Obsessive-Compulsive Disorder. *Depression and Anxiety*, **19**: 225–233.

Stahl, S.M., 2013. *Stahl's Essential Psychopharmacology*, Fourth Edition. ed. Cambridge University Press.

Starcevic, V., 2012. Benzodiazepines for Anxiety Disorders: Maximizing the Benefits and Minimising the Risks. *Advances in psychiatric treatment*, **18**: 250–258.

Stuart, G.W., 2009. *Principles and Practice of Psychiatric Nursing*, 10 Edition. ed. Elsevier.

Supratman, D., 2018. Prevalensi Usia Pemuda dan Ketahanan Nasional (Narkotika dan Ancaman Lost Generation) **1**: 118–127.

Tanzi, M.G., 2016. Stopping Antidepressants: Clinical Considerations. *Pharmacy Today*, **22**: 38–39.

Thomas, S.E., Randall, P.K., Book, S.W., dan Randall, C.L., 2007. A Complex Relationship Between Co-occurring Social Anxiety and Alcohol Use

Disorders: What Effect Does Treating Social Anxiety Have on Drinking?: Impact of Treating Social Anxiety on Drinking. *Alcoholism: Clinical and Experimental Research*, **32**: 77–84.

Trevor, A.J., 2018. Sedative-Hypnotic Drugs, dalam: Katzung, B.G. (Editor), *Basic & Clinical Pharmacology*. Mc Graw Hill, hal. 381–395.

Wang, S.-M., Kim, J.-B., Sakong, J.K., Suh, H.-S., Oh, K.S., Woo, J.-M., dkk., 2016. The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study. *Clinical Psychopharmacology and Neuroscience*, **14**: 177–183.

Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., dan DiPiro, C.V., 2015. *Pharmacotherapy Handbook*, Ninth. ed. McGraw-Hill Education, New York.

Whalen, K., Feild, C., dan Radhakrishnan, R., 2019. *Lippincott Illustrated Reviews Pharmacology*, Seventh. ed. Wolters Kluwer.

Whitehead, A.L., Julious, S.A., Cooper, C.L., dan Campbell, M.J., 2016. Estimating the Sample Size for a Pilot Randomised Trial to Minimise the Overall Trial Sample Size for the External Pilot and Main Trial for a Continuous Outcome Variable. *Statistical Methods in Medical Research*, **25**: 1057–1073.

WHO, 2017. *Depression and Other Common Mental Disorders : Global Health Estimates*. World Health Organization, Geneva, Switzerland.

WHO, 2020. 'Management Of Substance Abuse', WHO. URL: https://www.who.int/substance_abuse/terminology/definition1/en/ (diakses tanggal 3/12/2020).

Willems, I.A.T., Gorgels, W.J.M.J., Oude Voshaar, R.C., Mulder, J., dan Lucassen, P.L.B.J., 2013. Tolerance to Benzodiazepines Among Long-Term Users in Primary Care. *Family Practice*, **30**: 404–410.

Wu, C.-S., Wang, S.-C., Chang, I.-S., dan Lin, K.-M., 2009. The Association Between Dementia and Long-Term Use of Benzodiazepine in the Elderly: Nested Case–Control Study Using Claims Data. *The American Journal of Geriatric Psychiatry*, **17**: 614–620.